ArticleJournal for immunotherapy of cancer2018

Cost-effectiveness of nivolumab plus ipilimumab as first-line therapy in advanced renal-cell carcinoma.

Bin Wu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.